Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity.
BACKGROUND
The prevalence of asymptomatic hyperlactatemia among HIV-infected individuals has been reported to be 4% to 36%. This variability may reflect differences in the definition of and risk factors for hyperlactatemia and/or techniques for venous lactate collection.


METHODS
We examined the prevalence of elevated venous lactate collected in accordance with Adult AIDS Clinical Trials Group (AACTG) guidelines among HIV-infected and nucleoside analogue-treated subjects with risk factors associated with hyperlactatemia. Sustained hyperlactatemia was defined as 2 consecutive levels >or=1.5 but <or=4 times the upper limit of normal (ULN) within 30 days.


RESULTS
Eighty-three subjects were enrolled. Two thirds had >or=2 risk factors, with 11% having >4 risk factors. The median entry venous lactate level was 1.2 mmol/L (range: 0.7-5.1 mmol/L). Two subjects had a lactate level >1.5 times the ULN: 1 with a value of 2.1 times the ULN at entry and a week 2 level of 1.2 times the ULN and a second subject with a week 2 value of 1.9 times the ULN but an entry level of 1.4 times the ULN. The latter subject developed symptomatic lactic acidosis 3 weeks following study discontinuation.


CONCLUSIONS
Sustained asymptomatic hyperlactatemia among subjects with risk factors associated with hyperlactatemia was not observed when venous lactate was measured in a standardized fashion. One case of hyperlactatemia that evolved into symptomatic lactic acidosis was diagnosed soon after the completion of the study, however. Our findings indicate that asymptomatic hyperlactatemia is either very rare or an artifact of collection technique.
Wohl
David A
DA
Department of Medicine, University of North Carolina, Chapel Hill, USA. wohl@med.unc.edu
Pilcher
Christopher D
CD
Evans
Scott
S
Revuelta
Manuel
M
McComsey
Grace
G
Yang
Yijun
Y
Zackin
Robert
R
Alston
Beverly
B
Welch
Stacey
S
Basar
Michael
M
Kashuba
Angela
A
Kondo
Pualani
P
Martinez
Ana
A
Giardini
Jeffrey
J
Quinn
Joseph
J
Littles
Melvin
M
Wingfield
Harry
H
Koletar
Susan L
SL
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D005006:Ethnicity; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007773:Lactates / Q000097:blood*; D008297:Male; D008659:Metabolic Diseases / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D008928:Mitochondria / Q000473:pathology*; D015995:Prevalence; D012307:Risk Factors; D014803:Vitamin B Complex / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D007773:Lactates; D014803:Vitamin B Complex